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Key Points




G3139 can be safely
added to conventional
chemotherapy for
older patients with
AML.
Adding G3139 did
not improve complete
remission rates, but
patients with
secondary AML had
improved DFS.

Overexpression of B-cell leukemia/lymphoma 2 (BCL2) renders acute myeloid leukemia
(AML) cells resistant to chemotherapy and has been associated with unfavorable
outcomes. Oblimersen (G3139) is a phosphorothioate 18-mer antisense oligonucleotide
directed against the ﬁrst 6 BCL2 codons. In a phase 1 study of AML patients treated with
G3139, cytarabine, and daunorubicin induction with cytarabine consolidation, no
antisense-related toxicity was reported, and BCL2 downregulation occurred in patients
achieving complete remission. In this phase 3 trial, untreated older AML patients were
randomized to cytarabine (100 mg/m2 per day on days 4-10) and daunorubicin (60 mg/m2
per day on days 4-6) followed by cytarabine consolidation (2000 mg/m2 per day on days
4-8) with (arm A) or without (arm B) G3139 (7 mg/m2 per day on days 1-10 [induction] or
days 1-8 [consolidation]). A total of 506 patients were enrolled. No differences in toxicity
were observed between arms. Estimated overall survival (OS) at 1 year was 43% for arm
A and 40% for arm B (1-sided log rank P 5 .13), with no differences in disease-free (DFS;
P 5 .26) or event-free survival (P 5 .80). Subgroup analyses showed patients age ,70
years in arm A had improved OS by 1 month vs those in arm B (P 5 .04), and patients
with secondary AML in arm A had better DFS vs those in arm B (P 5 .04). We conclude
that addition of G3139 to chemotherapy failed to improve outcomes of older AML
patients. However, more effective means of inhibiting BCL2 are showing promising
results in combination with chemotherapy in AML. This trial was registered at www.
clinicaltrials.gov as #NCT00085124.

Submitted 20 January 2021; accepted 8 March 2021; published online 12 July 2021.
DOI 10.1182/bloodadvances.2021004233.

The full-text version of this article contains a data supplement.
ß 2021 by The American Society of Hematology
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Introduction

regard to CR rate, DFS, event-free survival (EFS), and OS in previously untreated AML patients age $60 years.

The identiﬁcation of mechanisms of leukemogenesis that lead to
maturation arrest, myeloid blast proliferation, and resistance to chemotherapy has helped guide the development of targeted therapies
for the treatment of patients with acute myeloid leukemia (AML).
While applicable to all patients, those age $60 years are in need of
novel induction strategies, because they often have adverse cytogenetic and/or molecular abnormalities that confer an inferior response
to standard cytarabine and anthracycline chemotherapy.1,2 Current
treatment approaches attempt to improve complete remission (CR)
rates by adding an agent with a unique mechanism of action that
will not increase the toxicity of standard chemotherapy and will possibly prolong disease-free (DFS) and overall survival (OS).3,4

Patients and methods

Oblimersen sodium (G3139) is an 18-mer phosphorothioate oligodeoxynucleotide antisense molecule designed to bind the ﬁrst 6 codons of human BCL2 messenger RNA (mRNA). In a phase 1 trial
of G3139 in combination with escalated doses of ﬂudarabine, cytarabine, and granulocyte colony-stimulating factor in patients with refractory or relapsed acute leukemia, downregulation of BCL2 mRNA
after G3139 administration was observed. The agent was well tolerated, with 45% of patients achieving CR or CR with incomplete
count recovery.11 In a larger phase 1 trial of 29 patients age $60
years with untreated AML, G3139 in combination with standard cytarabine and anthracycline induction and high-dose cytarabine consolidation was deemed safe and tolerable, and BCL2
downregulation was observed to occur preferentially in the 14 patients who achieved CR.12 Indeed, those who achieved CR had a
decrease in median BCL2 mRNA copies compared with baseline
(P 5 .03), whereas nonresponders had an increase in median
BCL2 mRNA copies (P 5 .05).12
The primary objective of the Cancer and Leukemia Group B
(CALGB) 10201 study was to determine whether the addition of
G3139 to cytarabine/daunorubicin induction chemotherapy and
high-dose cytarabine consolidation therapy improves outcomes with
2776
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Patients age $60 years with an unequivocal diagnosis of AML
based on World Health Organization and/or French-American-British classiﬁcation, excluding acute promyelocytic leukemia, were enrolled at CALGB centers and through the Cancer Trials Support
Unit. CALGB is now part of the Alliance for Clinical Trials in Oncology (Alliance). Patients with a history of antecedent myelodysplasia
(MDS) who had not received prior cytotoxic chemotherapy and
those with therapy-related AML were eligible. Signed informed consent was obtained before study entry. G3139 was provided to the
National Cancer Institute under a Clinical Research and Development Agreement between Genta, Inc., and the National Cancer Institute, whereby the drug was shipped directly to the institutions
where the patients were to be treated.
For remission induction, patients were randomized 1:1 to 1 of the 2
treatment arms, as shown in Table 1. Patients in arm A received 7
mg/kg of G3139 per day as a continuous IV infusion (CIVI) through
a central line on days 1 to 10; 100 mg/m2 of cytarabine per day
was administered as a CIVI through a central line on days 4 to 10,
and 60 mg/m2 of daunorubicin per day was administered by IV
push through a central line on days 4 to 6. G3139 was administered before the initiation of chemotherapy based on the hypothesis
that downregulation of BCL2 would lower the apoptotic threshold
and restore chemosensitivity in otherwise resistant leukemic cells. A
bone marrow (BM) aspirate and biopsy were performed on day 17
for patients enrolled in arm A to determine the need for a second induction cycle. Patients enrolled in arm B received cytarabine and
daunorubicin alone via the same doses, schedules, and methods of
administration as patients enrolled in arm A; however, a BM aspirate
and biopsy were performed on day 14 to assess the need for a second induction cycle. The dose of daunorubicin was reduced if the
bilirubin levels were elevated (daunorubicin was reduced by 25%
for total bilirubin between 2 and 3 mg/dL and by 50% for total bilirubin .3 mg/dL). Patients with residual leukemia received a second
induction course according to the arm to which they had been randomized. Patients in arm A received 7 mg/kg of G3139 per day by
CIVI on days 1 to 8, 100 mg/m2 of cytarabine per day on days 4 to
8, and 60 mg/m2 of daunorubicin per day on days 4 to 5. Patients
enrolled in arm B received 100 mg/m2 of cytarabine per day by
CIVI on days 1 to 5 and 60 mg/m2 of daunorubicin per day by IV
push on days 1 to 2. Regardless of treatment arm, BM aspiration
and biopsy were performed within 1 week after recovery of absolute
neutrophil count $1500/mL and platelets $100 3 109/L, but no
later than on day 42 of the second induction. Patients who were
documented to have residual leukemia at this time were removed
from protocol therapy and followed for survival.
Patients who achieved CR were eligible to receive consolidation according to their initial randomization. Patients were required to have
resolution of all signiﬁcant induction toxicities to grade ,2. Patients
who had experienced a decline in left ventricular ejection fraction to
,35% and had been randomized to receive G3139 had it omitted
from consolidation therapy. Patients enrolled in arm A received 7
mg/kg of G3139 per day by CIVI on days 1 to 8 and 2000 mg/m2
13 JULY 2021 • VOLUME 5, NUMBER 13
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Mitochondrial processes involved in cell survival and death signaling
are critically important in cancer biology, because defects within the
intrinsic apoptotic pathway confer a survival advantage and contribute to chemotherapy resistance.5 The proteins that seem to exert
the most control over this pathway are those within the B-cell leukemia/lymphoma 2 (BCL2) family.6 By binding to proapoptotic moieties, which disrupt mitochondrial integrity and allow the release of
cytochrome c, BCL2 prevents the initiation of apoptosis and thus
prolongs cell survival.7 Because the percentage of BCL2-expressing
cells increases in patients with AML, the CR rates after intensive
treatment decrease, and patients with BCL2-expressing leukemia
($20% BCL21 cells) have shorter survival than those with BCL22
leukemia (,20% BCL21 cells).8 Additionally, upregulation of BCL2
within leukemic stem cells may promote leukemic stem cell survival
in response to stressful stimuli such as chemotherapy or radiotherapy.9 The small-molecule oral BCL2 inhibitor venetoclax was recently
approved for the treatment of newly diagnosed older and/or unﬁt
AML patients in combination with hypomethylating agents or lowdose cytarabine based on high rates of durable remissions.10 On
the basis of these observations, downregulation of the BCL2 gene
itself as a therapeutic strategy could be used as a way to lower the
apoptotic threshold and restore chemosensitivity.

Eligibility criteria and study design

Table 1. Chemotherapy regimen
G3139

Cytarabine

Daunorubicin

7 mg/kg per d, d 1-10

100 mg/m2 per d, d 4-10

60 mg/m2 per d, d 4-6

Arm A
Induction

2

Reinduction

7 mg/kg per d, d 1-8

100 mg/m per d, d 4-8

Consolidation

7 mg/kg per d, d 1-8

2000 mg/m2 per d, d 4-8

60 mg/m2 per d, d 4-5

Arm B
100 mg/m2 per d, d 1-7

Induction

2

Reinduction

100 mg/m per d, d 1-5

60 mg/m2 per d, d 1-3
60 mg/m2 per d, d 1-2

2

2000 mg/m per d. d 1-5

Consolidation

Patients who experienced grade 3 or 4 nonhematologic toxicity during G3139 infusion during remission induction or consolidation that
was considered to be probably or possibly related to G3139 were
managed according to dose-reduction and discontinuation guidelines set forth in the protocol.

Cytogenetic analyses
Pretreatment cytogenetic analyses of BM and/or blood samples
were performed by CALGB-approved institutional cytogenetic laboratories, and the results were conﬁrmed by central karyotype review.13,14 For the karyotype to be designated as normal, at least 20
metaphase cells from BM specimens that were subjected to shortterm (24- and/or 48-hour) culture must have been analyzed and no
clonal abnormality found.13,14

Molecular analyses
The mutational status of NPM1, ASXL1, RUNX1, and TP53 genes
was determined centrally at The Ohio State University by targeted
amplicon sequencing using the MiSeq platform (Illumina, San Diego,
CA) as described previously.15 Determination of CEBPA mutational
status and testing for internal tandem duplication of the FLT3 gene
were performed as described by Marcucci et al16 and Whitman et
al,17 respectively. Patients for whom cytogenetic and molecular data
were available were categorized according to the 2017 European
LeukemiaNet (ELN) genetic risk classiﬁcation.18

of 0.025 (1 sided); this required a target sample size of 500 patients to be evenly randomized to 1 of the 2 treatments to achieve
the target number of events of 350 deaths. DFS was deﬁned as the
time from remission to relapse or death resulting from any cause.
EFS was deﬁned as the time from randomization to relapse, death
resulting from any cause, or failure to achieve CR by the end of the
induction courses. Interim efﬁcacy analyses were planned for OS,
DFS, EFS, and CR rates to coincide with semiannual CALGB/Alliance Data and Safety Monitoring B meetings, beginning after 25%
of the expected events for each end point (OS, DFS, EFS, and CR
rate) had been observed. Each analysis was to use a Lan-DeMets
spending function analog of a 1-sided O’Brien-Fleming stopping
rule truncated at 0.001 when relevant.
x2 tests were used to compare categorical variables,19 and 2 sample Student t tests were used to compare continuous variables.20
The distributions of time-to-event end points were estimated using
the Kaplan-Meier method21 and compared between 2 treatment
arms using log-rank tests.22 Hazard ratios (HRs) and 95% conﬁdence intervals (CIs) were estimated using the Cox proportional
hazards model.23 P value for primary analysis of OS was determined
by 1-sided log-rank test per study design, and P values for all other
end points and secondary analyses were 2 sided. All primary analyses were performed by intent to treatment. The secondary analyses
were performed among patients who were eligible and received at
least 1 cycle of treatment. Subgroup analyses based on pretreatment clinical and cytogenetic characteristics were planned. Clinical
data were locked on 14 July 2016, although the molecular analyses
were more recently completed.
Data collection and statistical analyses were conducted by the Alliance Statistics and Data Center. Data quality was ensured by review of data by the Alliance Statistics and Data Center and by the
study chairperson following Alliance policies.

Results

Statistical analyses
The primary objective was to determine whether the addition of
G3139 to cytarabine/daunorubicin induction chemotherapy and
high-dose cytarabine consolidation therapy improves outcomes with
regard to OS, DFS, EFS, and CR rates in previously untreated AML
patients age $60 years. There were no stratiﬁcation factors used in
the randomization. The primary end point was OS, which was deﬁned as the time from randomization to death resulting from any
cause. This study was designed to have a power of 0.77 to detect
a 33% increase in median OS (9 vs 12 months) with a type 1 error
13 JULY 2021 • VOLUME 5, NUMBER 13

Patient characteristics
A total of 506 patients were enrolled between October 2004 and
October 2006 at 75 CALGB member institutions and their afﬁliated
hospitals; 254 patients were randomized to arm A and 252 to arm B
(supplemental Figure 1). Sixty-eight patients with either therapy-related AML or AML after prior MDS were enrolled in arm A, and 59
were enrolled in arm B. Eleven patients never began protocol therapy
after they were registered and randomized; they were included in the
intent-to-treat analysis but excluded from the correlative analyses. A
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of cytarabine per day IV over 3 hours on days 4 to 8. Patients enrolled in arm B received 2000 mg/m2 of cytarabine per day IV over
3 hours on days 1 to 5. In both arms, serial neurologic evaluation
was performed before and after each infusion of cytarabine, and
corticosteroid ophthalmic drops to each eye were administered 4
times daily and continued for at least 24 hours after the ﬁnal dose
of cytarabine. Patients who completed the ﬁrst consolidation were
eligible to proceed to a second cycle after conﬁrmation of continued
remission on a BM aspirate and biopsy.

patient age 48.5 years old was included in this group of 11 patients.
Baseline clinical characteristics are listed in Tables 2 and 3.

Table 2. Patient characteristics
Characteristic

Response to induction chemotherapy

.92

Age, y
Mean (SD)

69.8 (6.4)

69.7 (6.3)

69.7 (6.4)

Median

69.6

68.8

69.0

Range*

60.1-88.3

48.5-86.6

48.5-88.3
.65

Age group
,70

137 (53.9)

141 (56.0)

278 (54.9)

$70

117 (46.1)

111 (44.0)

228 (45.1)

Female

99 (39.0)

100 (39.7)

199 (39.3)

Male

155 (61.0)

152 (60.3)

307 (60.7)

American Indian or Alaska Native

2 (0.8)

2 (0.8)

4 (0.8)

Asian

4 (1.6)

1 (0.4)

5 (1.0)

Black or African American

11 (4.3)

11 (4.4)

22 (4.3)

Native Hawaiian or Paciﬁc Islander

1 (0.4)

1 (0.4)

2 (0.4)

Consolidation treatment

Not reported

1 (0.4)

0 (0.0)

1 (0.2)

Of the 277 patients who achieved CR, 211 received at least 1 cycle of consolidation. By arm, 70 patients (68%) in arm A and 73
(68%) in arm B completed both cycles of consolidation. Five patients in arm A did not receive G3139 during consolidation. None
had experienced a decline in cardiac ejection fraction as the reason
for discontinuation. Patients who did not receive both cycles of chemotherapy withdrew from the study because of disease progression
(n 5 29), toxicity (n 5 14), switching to an alternative therapy (n 5
4), or death (n 5 6).

Unknown

8 (3.1)

11 (4.4)

19 (3.8)

227 (89.4)

226 (89.7)

453 (89.5)

6 (2.4)

5 (2.0)

11 (2.2)

232 (91.3)

226 (89.7)

458 (90.5)

16 (6.3)

21 (8.3)

37 (7.3)

0

87 (34.3)

64 (25.4)

151 (29.8)

1

137 (53.9)

143 (56.7)

280 (55.3)

2

22 (8.7)

41 (16.3)

63 (12.5)

3

8 (3.1)

4 (1.6)

12 (2.4)

Post-MDS

55 (21.7)

42 (16.7)

97 (19.2)

De novo AML

186 (73.2)

193 (76.6)

379 (74.9)

13 (5.1)

17 (6.7)

30 (5.9)

Treatment toxicities during consolidation
During consolidation therapy, .90% of patients experienced grade
4 neutropenia and thrombocytopenia. Febrile neutropenia and grade
3 or 4 infection were common in both groups, but not as frequent
as during induction (febrile neutropenia: arm A, 38% vs arm B,
47%; infection: arm A, 27% vs arm B, 33%). Grade 3 rash (4% vs
5%) and diarrhea (6% vs 2%) were also less common during consolidation than during induction. There were 9 patients (4%) in arm
A who developed grade 3 ataxia compared with 2 in arm B (1%).
2778
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.78

Race

White

.66

Ethnicity
Hispanic or Latino
Non-Hispanic
Unknown

.01

Performance status

Treatment toxicities during induction
During induction, toxicities that commonly follow intensive chemotherapy for AML were observed. Grade 4 neutropenia and thrombocytopenia were nearly universal, occurring in .90% of patients in
both groups. The most common grade 3 or 4 nonhematologic toxicities were febrile neutropenia and infection, occurring equally between the 2 arms (febrile neutropenia: arm A, 73% vs arm B, 77%;
infection: arm A, 57% vs arm B, 56%). The next most common toxicities included electrolyte abnormalities, dyspnea, diarrhea, and fatigue. Twelve patients in arm A and 8 in arm B developed left
ventricular systolic dysfunction during induction; this difference was
not statistically signiﬁcant. One patient in arm A developed tumor lysis syndrome compared with 2 in arm B. Deaths during the ﬁrst 30
days of treatment are reported in Table 4 and did not differ by treatment arm (13% vs 12%; P 5 .81). Table 6 lists all grade $3 nonhematologic adverse events that occurred in $10% of patients
during the induction course.

.87

Sex

.30

Disease type

Therapy-related AML

Data are given as n (%) unless otherwise indicated.
SD, standard deviation.
One patient (age 48.5 y) was registered in error and randomized but not treated. This
patient was included in all intent-to-treat analyses.
*

There were 4 treatment-related deaths (arm A, n 5 2; arm B, n 5
2) during consolidation.

Survival and long-term follow-up
Among the 506 randomized patients, median follow-up was 100
months (range, 1-119) for the 41 surviving patients. There were no
signiﬁcant differences between the 2 arms in OS, EFS, or DFS (Table 4; Figures 1-3). Median OS was 9 months (95% CI, 7-12) in
the G3139 group and 9 months (95% CI, 8-11) in the control
group (1-sided log-rank P 5 .13), with an HR of 0.9 (95% CI, 0.751.08). The 1-year OS rate was 43% in the G3139 group and 40%
in the control group. Median EFS was 3 months (95% CI, 2-4) in
the G3139 group and 3 months (95% CI, 3-5) in the control group
(P 5 .80), with an HR of 0.98 (95% CI, 0.82-1.17). Median DFS
13 JULY 2021 • VOLUME 5, NUMBER 13
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Of the 506 patients, 277 achieved remission. The CR rate was
53% in arm A vs 56% in arm B. There was no statistical difference
between the 2 arms (P 5 .53; Table 4). Sixty-four patients (26%) in
arm A and 66 (27%) in arm B (P 5 .84) received a second induction course. Subgroup analysis by age (,70 vs $70 years; supplemental Table 1) and by AML type (supplemental Table 2) showed
no difference in CR rate between the 2 arms. Response rates of patients classiﬁed according to 2017 ELN genetic risk classiﬁcation18
are shown in Table 5. There were no statistically signiﬁcant differences in CR rate between patients in arm A and those in arm B in
any of the 2017 ELN genetic risk groups. A minority of patients in
arm A from select institutions had pretreatment and follow-up samples submitted for reverse transcription polymerase chain reaction
analysis of BCL2 expression, limiting the interpretation of the results.
Given that these ﬁndings are inconclusive, they are not included
here.

Arm A: G3139 Arm B: control
Total
(n 5 254)
(n 5 252)
(N 5 506) P

Table 3. Cytogenetic and molecular features
Arm A: G3139
(n 5 190)

Arm B: control
(n 5 193)

Total
(n 5 383)

Normal karyotype

76 (40)

85 (44)

161 (42)

Complex karyotype

Characteristic

.58†

Cytogenetic group

38 (20)

85 (22)

9 (5)

5 (3)

14 (4)

Other balanced rearrangements

9 (5)

11 (6)

20 (5)

Unbalanced abnormalities in noncomplex karyotype

39 (21)

36 (19)

75 (20)

No sample received or rejected cytogenetics

10 (5)

18 (9)

28 (7)

39 (22)

34 (19)

73 (21)

.57‡

2017 ELN genetic risk group

Intermediate

24 (13)

18 (10)

42 (12)

Adverse

37 (37)

71 (41)

138 (39)

Unclassiﬁable

50 (28)

52 (30)

102 (29)

CEBPA double mutation

.95

Mutated

3 (3)

3 (3)

6 (3)

92 (97)

97 (97)

189 (97)

Mutated

27 (29)

34 (38)

61 (34)

WT

65 (71)

56 (62)

121 (66)

Present

14 (11)

27 (23)

41 (17)

Absent

108 (89)

92 (77)

200 (83)

WT
NPM1

.23

FLT3 ITD

.02

ASXL1

.02

Mutated

6 (7)

16 (18)

22 (12)

86 (93)

75 (82)

160 (88)

Mutated

14 (15)

13 (14)

27 (15)

WT

78 (85)

77 (86)

155 (85)

Mutated

15 (16)

10 (11)

25 (14)

WT

77 (84)

80 (89)

157 (86)

WT
RUNX1

.88

TP53

.31

Data are given as n (%).
CBF, core binding factor; ITD, internal tandem duplication; WT, wild type.
*
P values from x2 test.
†
No sample received or rejected cytogenetics; omitted from P value calculation.
‡
Unclassiﬁable; omitted from P value calculation.

was 8 months (95% CI, 7-12) in the G3139 group and 8 months
(95% CI, 7-11) in the control group (P 5 .26), with an HR of 0.87
(95% CI, 0.67-1.11).
Subgroup analysis showed no signiﬁcant differences between the 2
arms in EFS or DFS based on age (supplemental Table 1). However, OS for patients age ,70 years in arm A was signiﬁcantly longer
than OS for patients age ,70 years in arm B, with a median of 10
vs 9 months (P 5 .04; supplemental Table 1). A subgroup analysis
based on AML type showed no signiﬁcant differences between the
2 arms in EFS or OS (supplemental Table 2). However, DFS for patients with secondary AML in arm A was signiﬁcantly improved

13 JULY 2021 • VOLUME 5, NUMBER 13

compared with DFS for this patient subset in arm B, with a median
of 10 vs 6 months (P 5 .04; supplemental Table 2).
A total of 46 patients underwent stem cell transplantation. A majority
received an allogeneic hematopoietic cell transplantation (alloHCT)
from either a matched sibling (n 5 25) or matched unrelated donor
(n 5 11; supplemental Table 3). Three patients received an alloHCT
from an alternative donor source (ie, either umbilical cord blood or
haploidentical transplant). Seven patients underwent autologous
transplantation, 3 using BM and 4 using peripheral blood stem cells.
There was no difference in the number of patients undergoing transplantation by arm (n 5 24 vs 22; P 5 .99).
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47 (25)

CBF AML

Favorable

P*

Table 4. Intent-to-treat response and survival
End point

Arm A: G3139

Arm B: control

135/254

142/252

0.53 (0.47-0.59)

0.56 (0.50-0.63)

228/254

237/252

P
.53

CR
Events/n
Rate (95% CI)

.13*

OS
Events/n
Median (95% CI), mo

9 (7.46-11.66)

9 (7.82-10.78)

1-y rate (95% CI)

0.43 (0.37-0.49)

0.4 (0.34-0.46)

2-y rate (95% CI)

0.22 (0.18-0.28)

0.18 (0.14-0.23)

Events/n

234/254

241/252

3 (1.94-4.34)

3 (2.56-5.49)

1-y rate (95% CI)

0.22 (0.17-0.28)

0.24 (0.19-0.30)

2-y rate (95% CI)

0.13 (0.09-0.18)

0.09 (0.06-0.14)

116/135

130/142

Median (95% CI), mo

.26

DFS
Events/n
Median (95% CI), mo

8 (7.10-11.70)

8 (6.90-10.51)

1-y rate (95% CI)

0.4 (0.32-0.49)

0.37 (0.30-0.46)

2-y rate (95% CI)

0.24 (0.18-0.32)

0.16 (0.11-0.24)

0.13 (0.09-0.18)

0.12 (0.08-0.17)

Early death rate during ﬁrst 30 d of induction therapy

.81

All patients (95% CI)
*

One-sided P value.

Table 5. Treatment response of AML patients categorized according to 2017 ELN genetic risk classiﬁcation
Favorable
End point

Arm A: G3139 Arm B: control

P

Events/n
Rate (95% CI)

31/39

24/34

Arm A: G3139 Arm B: control P

8/18

Events/n

26/39

28/34

Median (95% CI), mo

15 (8.84-74.54) 18 (13.96-33.41)

1-y rate (95% CI)

0.54 (0.37-0.68) 0.74 (0.55-0.85)

2-y rate (95% CI)

0.38 (0.24-0.53) 0.41 (0.25-0.57)

Events/n
Median (95% CI), mo

28/39
9 (2.07-14.98)

0.39 (0.27-0.50) 0.46 (0.35-0.58)

17/18

9 (5.12-10.91)

5 (1.22-7.82)

0.31 (0.14-0.50) 0.22 (0.07-0.43)
0.22 (0.08-0.40)

28/34
9 (1.97-19.65)

33/71

.30
22/24

.34
66/67

71/71

5 (3.29-6.87)

6 (4.34-8.67)

0.21 (0.12-0.31) 0.25 (0.16-0.36)

0.06 (0-0.22)

.56

EFS

.36
26/67

0.58 (0.39-0.78) 0.44 (0.21-0.67)
.54

OS

Arm A: G3139 Arm B: control P*

.37
14/24

0.79 (0.67-0.92) 0.71 (0.56-0.86)

Adverse
*

.38

CR

0.06 (0.02-0.13) 0.10 (0.04-0.18)
.57

.25

23/24

17/18

66/67

71/71

2 (1.38-6.57)

2 (1.12-2.83)

2 (1.41-1.97)

2 (1.48-2.56)

1-y rate (95% CI)

0.36 (0.21-0.51) 0.44 (0.27-0.60)

0.14 (0.04-0.31) 0.11 (0.02-0.30)

0.06 (0.02-0.13) 0.15 (0.08-0.25)

2-y rate (95% CI)

0.33 (0.19-0.48) 0.26 (0.13-0.42)

0.09 (0.02-0.25)

0.06 (0-0.22)

0.03 (0.01-0.07) 0.07 (0.03-0.15)

18/24

13/14

7/8

25/26

33/33

19 (7.33-41.13)

5 (1.28-7.16)

6 (1.65-14.45)

5 (3.22-6.18)

8 (4.60-11.96)

.83

DFS
Events/n
Median (95% CI), mo

20/31
14 (7.03 to 1)

.51

.42

1-y rate (95% CI)

0.52 (0.33-0.67) 0.63 (0.40-0.78)

0.16 (0.03-0.39) 0.25 (0.04-0.56)

0.15 (0.05-0.31) 0.33 (0.18-0.49)

2-y rate (95% CI)

0.42 (0.25-0.58) 0.42 (0.22-0.60)

0.16 (0.03-0.39) 0.13 (0.01-0.42)

0.08 (0.01-0.22) 0.12 (0.04-0.26)

Early death rate during ﬁrst 30 d of induction therapy
All patients (95% CI)
*

Intermediate
*

.84
0.10 (0.01-0.20) 0.09 (0-0.18)

.17
0.04 (0-0.12)

0.17 (0-0.34)

.53
0.16 (0.08-0.25) 0.13 (0.05-0.20)

P values for CR from x2 test; for time-to-event variables, from log-rank test.
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EFS

Table 6. Grade $3 nonhematologic adverse events
Arm A: G3139 Arm B: control
Total
(n 5 247)
(n 5 244)
(n 5 491)

Adverse event

P*

Febrile neutropenia

181 (73)

187 (77)

368 (75)

.41

Infection

138 (56)

138 (57)

276 (56)

.93

Hypokalemia

57 (23)

50 (20)

107 (22)

.51

Dyspnea

40 (16)

51 (21)

91 (19)

.20

Hypoxia

43 (17)

43 (18)

86 (18)

1.00

41 (17)

38 (16)

79 (16)

.81

Hyperglycemia

33 (13)

42 (17)

75 (15)

.26

Fatigue

32 (13)

37 (15)

69 (14)

.52

Hypocalcemia

32 (13)

33 (14)

65 (13)

.89

Hypotension

28 (11)

36 (15)

64 (13)

.29

Hyponatremia

33 (13)

30 (12)

63 (13)

.79

Diarrhea

28 (11)

32 (13)

60 (12)

.58

Hypoalbuminemia

39 (16)

17 (7)

56 (11)

.002

Pain

22 (9)

34 (14)

56 (11)

.09

Hyperbilirubinemia

23 (9)

32 (13)

55 (11)

.20

Rash/desquamation

24 (10)

28 (11)

52 (11)

.56

Anorexia

21 (9)

27 (11)

48 (10)

.36

Infection (other)

23 (9)

22 (9)

45 (9)

1.00

Renal failure

29 (12)

14 (6)

43 (9)

.03

Pneumonitis/pulmonary inﬁltrates

19 (8)

21 (9)

40 (8)

.74

Data are given as n (%).
Two-sided P values from Fisher’s exact test.

*

Arm:

For patients who did not receive an alloHCT (n 5 467), OS, DFS,
and EFS were also similar between the 2 arms (OS, P 5 .23; EFS,
P 5 .55; DFS, P 5 .17; supplemental Figures 8-10). However, for
patients with secondary AML who did not undergo transplantation,
G3139 was associated with improved OS and DFS as compared
with control (OS: median, 10 vs 7 months; P 5 .03; DFS: median,
10 vs 6 months; P , .01; supplemental Figures 11 and 12).

Discussion
Despite advances in our understanding of the biology of AML and
characterization of prognostic clinical and genetic factors, the overall
outcome remains poor for patients age .60 years.1,24,25 Given that
CR rates remain inferior to those of patients age ,60 years, attempts to target mechanisms leading to primary resistance to chemotherapy with novel induction strategies are needed.1 One
approach in AML, as well as in other hematologic malignancies, has
A: G3139

B: Control

100%
Events/N Median (95% CI) HR (95% CI)
A: G3139 228/254

Overall survival

75%

B: Control 237/252

9.07 (7.46,11.66) 0.9 (0.75,1.08)
9.17 (7.82,10.78)

ref

Log-rank
P = .13*
50%

25%

0%
0

6

12

18

24

30

36

Time (months)
Patients at risk
A: G3139 254

157

108

66

56

45

41

B: Control 252

157

100

65

44

32

26

Figure 1. OS. Kaplan-Meier curves for OS in the G3139 and control groups. Tick marks indicate censoring of data. *One-sided P value.
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Hypophosphatemia

A total of 19 patients in arm A and 20 in arm B received an alloHCT; no signiﬁcant differences in OS, EFS, or DFS were observed between the 2 arms (supplemental Figures 2-4). Because
allogeneic transplantation was an important alternative therapy, we
performed a sensitivity analysis of OS, EFS, and DFS, in which data
were censored at the time patients received an alloHCT. In this analysis, there was an 11% lower risk of death in arm A than in arm B
(HR, 0.89; 95% CI, 0.74-1.08), but the difference did not reach statistical signiﬁcance (P 5 .24; supplemental Figure 5). DFS and EFS
were also similar between the 2 arms after censoring at the time of
alloHCT (EFS, P 5 .99; DFS, P 5 .20; supplemental Figures 6 and
7).

Arm:

A: G3139

B: Control

100%
Events/N Median (95% CI) HR (95% CI)
A: G3139 234/254

2.78 (1.94,4.34) 0.98 (0.82,1.17)

B: Control 241/252

3.33 (2.56,5.49)

ref

Log-rank
P = .80
50%

25%

0%
0

6

12

18

24

30

36

Time (months)
Patients at risk
A: G3139

254

96

55

41

32

28

26

B: Control

252

98

60

35

23

21

18

Figure 2. EFS. Kaplan-Meier curves for EFS in G3139 and control groups. Tick marks indicate censoring of data.

Arm:

B: Control

A: G3139

100%
Events/N
A: G3139 116/135
B: Control 130/142

Disease-free survival

75%

Median (95% CI)

HR (95% CI)

8.21 (7.10,11.70) 0.87 (0.67,1.11)
7.52 (6.90,10.51)

ref

Log-rank
P = .26
50%

25%

0%
0

6

12

18

24

30

36

Time (months)
Patients at risk
A: G3139 135

85

53

41

32

26

24

B: Control 142

93

52

36

23

21

18

Figure 3. DFS. Kaplan-Meier curves for DFS in G3139 and control groups. Tick marks indicate censoring of data.
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Event-free survival

75%

100%

Arm:

A: G3139

1 - Favorable

3 - Intermediate

5 - Adverse

B: Control

2 - Favorable

4 - Intermediate

6 - Adverse

50%

25%

0%
0

6

12

18

24

30

36

Time (months)
Patients at risk
1 - Favorable G3139 39

31

21

17

15

15

15
11

2 - Favorable control 34

27

25

17

14

12

3 - Intermediate G3139 24

15

7

4

4

3

1

4 - Intermediate control 18

7

4

2

1

1

1

5 - Adverse G3139 67

30

14

5

4

2

2

6 - Adverse control 71

36

18

11

7

4

2

Figure 4. Kaplan-Meier estimates of OS in AML patients categorized according to 2017 ELN genetic risk classiﬁcation by treatment arm. Patients receiving
G3139 (arm A) and those in the control arm (arm B) were arranged into 3 genetic risk groups (favorable, intermediate, or adverse) based on their cytogenetic and molecular
genetic ﬁndings at diagnosis.18

been to develop agents that enhance apoptosis in leukemic cells.
Several proteins within the mitochondrial apoptotic pathway have
been identiﬁed as potential targets because of their antiapoptotic
function, including BCL2, BCL-XL, and MCL-1.6 Aberrant BCL2 expression has been associated with lower CR rates and poor outcomes in patients with AML, and we hypothesized that
downregulation of BCL2 expression may induce a lower apoptotic
threshold and restore chemosensitivity.8 Oblimersen sodium
(G3139) is an oligodeoxynucleotide antisense molecule designed to
hybridize to BCL2 mRNA, thus becoming a substrate for degradation and creating a net decrease in BCL2 translation.26 Early-phase
clinical trials of G3139 in combination with cytotoxic chemotherapy
showed the agent to be well tolerated and able to downregulate
BCL2 mRNA levels in select patients.11,12
In the current study, which enrolled older patients with newly diagnosed de novo and secondary AML, we assessed whether patients
randomized to receive G3139 in combination with standard intensive
cytarabine/daunorubicin induction chemotherapy and high-dose cytarabine consolidation would experience an improvement in CR rates
and other disease-speciﬁc outcomes when compared with those
randomized to arm B, who did not receive G3139. We observed no
13 JULY 2021 • VOLUME 5, NUMBER 13

added toxicities. G3139 was well tolerated in this group of patients
and did not seem to increase or prolong the adverse events normally
seen during anthracycline-based induction. However, when considering all treated participants, there were no overall differences in CR
rates, OS, DFS, or EFS between those who received G3139 and
those who did not, regardless of the 2017 ELN genetic risk group
(Table 5; Figures 4-6).18 Importantly, patients randomized to receive
G3139, who thus had a 3-day delay in starting cytotoxic chemotherapy, had similar clinical outcomes and did not experience a worse
early death rate compared with the control group. A subset analysis
showed that patients with secondary AML, deﬁned as therapy-related AML or AML after prior MDS, who received G3139 had improved DFS when compared with those who did not. Additionally,
for patients with secondary AML who received G3139 and did not
undergo transplantation, G3139 was associated with improved OS
and DFS when compared with the standard therapy arm.
There are limitations to the study. Given the small number of pretreatment and follow-up samples submitted for BCL2 expression
analysis, it is difﬁcult to determine whether the lack of beneﬁt between the 2 treatment groups was due to a lack of target inhibition
or other mechanisms that prevented response to chemotherapy.
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Overall survival

75%

Arm:
100%

A: G3139

1 - Favorable

3 - Intermediate

5 - Adverse

B: Control

2 - Favorable

4 - Intermediate

6 - Adverse

50%

25%

0%
0

6

12

18

24

30

36

13

12

Time (months)
Patients at risk
1 - Favorable G3139 39

25

14

13

13

2 - Favorable control 34

19

15

12

9

9

8

3 - Intermediate G3139 24

7

3

2

2

0

0

4 - Intermediate control 18

3

2

1

1

1

1

5 - Adverse G3139 67

11

4

4

2

2

2

6 - Adverse control 71

19

11

7

5

3

2

Figure 5. Kaplan-Meier estimates of EFS in AML patients categorized according to 2017 ELN genetic risk classiﬁcation by treatment arm. Patients receiving
G3139 (arm A) and those in the control arm (arm B) were arranged into 3 genetic risk groups (favorable, intermediate, or adverse) based on their cytogenetic and molecular
genetic ﬁndings at diagnosis.18

Antisense oligonucleotides are known to have issues with delivery,
targeting, and off-target effects,27 and it is not known whether these
played a role in this trial. Nonetheless, we did see some beneﬁt in
patients with secondary AML, usually a more refractory subgroup,
and this may suggest that this subtype is more sensitive to BCL2
downregulation.
Whereas G3139 attempts to inhibit BCL2 at the level of translation,
newer agents that target the BCL2 protein directly have been developed. Venetoclax is an oral highly selective BCL2 inhibitor that was
granted accelerated approval by the US Food and Drug Administration for chronic lymphocytic leukemia with chromosome 17p deletion
in April 2016.28 Given the concern for drug delivery and target accuracy with antisense molecules, the more potent direct inhibitory effect
of venetoclax would be an advantage over G3139. Preclinical studies
in primary AML samples in vitro and in xenograft models demonstrated that BCL2 inhibition resulted in cell death.29 Although singleagent venetoclax was well tolerated in patients, it had limited antileukemic activity in relapsed or refractory AML.30 However, early-phase
studies of venetoclax combined with low-intensity chemotherapy
demonstrated high response rates and longer OS in older adults
with previously untreated AML.31 The superiority of venetoclax-based
2784
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combination therapy has since been conﬁrmed in 2 separate phase
3 randomized trials. In the VIALE-A32 and VIALE-C33 trials, patients
with previously untreated AML were randomized to venetoclax or placebo plus azacitidine or low-dose cytarabine, respectively. Patients
randomized to venetoclax experienced a higher composite CR (CR
plus CR with incomplete hematologic recovery) and longer OS compared with those in the placebo arm of either trial. These results, in
addition to the tolerability of these regimens, have solidiﬁed venetoclax-based induction strategies as a standard of care for patients
with untreated AML. Additional trials of venetoclax in younger patients
and in combination with cytotoxic chemotherapy are under way.34
AML cells seem to be particularly dependent on BCL2 for their survival. The approval of venetoclax in combination with hypomethylating agents or low-intensity chemotherapy has already changed the
therapeutic landscape for older patients with AML. Whether using
an antisense molecule such as G3139 to lower the intracellular levels of BCL2 would provide any synergistic beneﬁt beyond the use
of venetoclax plus chemotherapy is uncertain. Although there has
been no further development of G3139, the concept of attacking
antiapoptotic proteins, as attempted in the current trial, may represent a new paradigm in AML therapy.
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Event-free survival
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100%
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A: G3139
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5 - Adverse

B: Control
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6 - Adverse

24
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0%
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Patients at risk
1 - Favorable G3139 31
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Figure 6. Kaplan-Meier estimates of DFS in AML patients categorized according to 2017 ELN genetic risk classiﬁcation by treatment arm. Patients receiving
G3139 (arm A) and those in the control arm (arm B) were arranged into 3 genetic risk groups (favorable, intermediate, or adverse) based on their cytogenetic and molecular
genetic ﬁndings at diagnosis.18
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